|
|
|
|
| LEADER |
05453cam a22005537i 4500 |
| 001 |
MUB03000024240 |
| 003 |
CZ BrMU |
| 005 |
20220912085510.0 |
| 008 |
220530t20152015ne |||||o|||||||||||eng d |
| STA |
|
|
|a EIZ
|b 333
|c EBSCO trvale nakupy
|d 2022-05-30
|
| 020 |
|
|
|a 9780124172135
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)ocn913530203
|
| 035 |
|
|
|a (OCoLC)913530203
|z (OCoLC)913694294
|z (OCoLC)920816765
|z (OCoLC)959423590
|
| 040 |
|
|
|a OPELS
|b cze
|e rda
|c OPELS
|d KNOVL
|d OCLCF
|d EBLCP
|d YDXCP
|d ZCU
|d DEBSZ
|d DXU
|d YDX
|d VGM
|d OCLCQ
|d S4S
|d COO
|d U3W
|d D6H
|d RRP
|d N$T
|d MERER
|d WYU
|d DCT
|d OCLCO
|d BOD037
|
| 072 |
|
7 |
|a 61
|x Lékařské vědy. Lékařství
|2 Konspekt
|9 14
|
| 080 |
|
|
|a 61:54
|2 MRF
|
| 080 |
|
|
|a 615:54
|2 MRF
|
| 245 |
0 |
4 |
|a The practice of medicinal chemistry /
|c edited by Camille Georges Wermuth, David Aldous, Pierre Raboisson, Didier Rognan
|
| 250 |
|
|
|a Fourth edition
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c [2015]
|
| 264 |
|
4 |
|c ©2015
|
| 300 |
|
|
|a 1 online zdroj (xxii, 880 stran) :
|b ilustrace
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a počítač
|b c
|2 rdamedia
|
| 338 |
|
|
|a online zdroj
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Front Cover; The Practice of Medicinal Chemistry; Copyright Page; Contents; List of Contributors; Foreword; Preface to the Fourth Edition; Preface to the Third Edition; Preface to the Second Edition; Preface to the First Edition; I. General Aspects of Medicinal Chemistry; 1 Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems; I. Definitions and Objectives; A Medicinal Chemistry and Related Disciplines and Terms; B Drugs and Drug Substances; C Stages of Drug Development; II. Drug Activity Phases; A The Pharmaceutical Phase.
|
| 505 |
8 |
|
|a B The Pharmacokinetic PhaseC The Pharmacodynamic Phase; D The Road to Successful Drug Development?; III. Drug Classification Systems; A Classification by Target and Mechanism of Action; 1 Targets; 2 Mechanisms of Action; B Other Classification Systems; References; 2 Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies; I. Introduction; II. Drug Discovery Approaches and Screening Cascades; A Target Based Screening; B Phenotypic Screening; III. In Vitro Assays; A Primary Assays; Glossary; 1 Binding assays; 2 Binding Studies: Principles and Analysis.
|
| 505 |
8 |
|
|a 3 Enzyme Assays4 Types of Enzyme Inhibition and Their Analysis; A Reversible Inhibitors; B Irreversible Inhibitors; C Competitive Inhibitors; D Noncompetitive Inhibitors; E Uncompetitive Inhibitors; 5 Functional Assays; 6 Functional Studies and Their Analysis; A Agonist Concentration-Effect (E/[A]) Curves; B Full Agonists, Partial Agonists, and Inverse Agonists; C Optimizing Agonists; D Analysis of Antagonists; Competitive Antagonists; Irreversible, Noncompetitive, and Allosteric Antagonists; B Compound Interference in Primary Assays: Artifacts and False Positives; C Assay Biostatistics.
|
| 505 |
8 |
|
|a D Selectivity, Cytotoxicity, and Species Cross-over. 1 Selectivity; 2 Cytotoxicity; 3 Species Crossover; E Cellular and Tissue Functional Responses; IV. Ex Vivo Assays; V. In Vivo Assays; A Pharmacokinetic Models; B Efficacy Models; C Safety Testing; Acknowledgements; References; 3 Drug Targets, Target Identification, Validation, and Screening; I. Introduction; II. What is a Drug Target?; III. The Purpose of Target Identification; A Target-Based Screening; B Phenotypic Screening; C Fast Follower Strategy; IV. Target Options and Treatment Options; V. Target Deconvolution and Target Discovery.
|
| 505 |
8 |
|
|a VI. Methods for Target Identification and ValidationA Affinity Chromatography; B Genetic Methods; C Haploinsufficiency Profiling in Yeast; D Analysis of Resistant Mutants; E siRNA for Target Validation; F Yeast Three-Hybrid System; G DNA Microarrays; H Comparative Profiling; I Analysis of the Pathophysiology; J The Study of Existing Drugs; K Systems Biology; L In Silico Simulation of the Human Patient; VII. Target Validation; VIII. Conclusion; References; II. Lead Compound Discovery Strategies; 4 Strategies in the Search for New Lead Compounds or Original Working Hypotheses; I. Introduction.
|
| 533 |
|
|
|a Elektronická reprodukce.
|n Přístup pouze pro oprávněné uživatele
|
| 650 |
0 |
7 |
|a lékařská chemie
|7 ph115192
|2 czenas
|
| 650 |
0 |
7 |
|a farmaceutická chemie
|7 ph114523
|2 czenas
|
| 650 |
0 |
9 |
|a medical chemistry
|2 eczenas
|
| 650 |
0 |
9 |
|a pharmaceutical chemistry
|2 eczenas
|
| 655 |
|
7 |
|a e-knihy online
|2 CZ-BrMU
|
| 655 |
|
9 |
|a e-books online
|2 eCZ-BrMU
|
| 700 |
1 |
|
|a Wermuth, Camille Georges
|7 xx0178053
|4 edt
|
| 700 |
1 |
|
|a Aldous, David
|q (David John)
|7 ntk20181004473
|4 edt
|
| 700 |
1 |
|
|a Raboisson, Pierre
|7 ntk20181004476
|4 edt
|
| 700 |
1 |
|
|a Rognan, Didier,
|d 1962-
|7 ntk20181004480
|4 edt
|
| 776 |
0 |
8 |
|i Tištěná verze:
|t Practice of medicinal chemistry.
|z 978-0-12-417205-0
|
| 856 |
4 |
1 |
|z Elektronická verze přístupná pouze pro studenty a pracovníky MU
|u https://ezproxy.muni.cz/login?url=https://search.ebscohost.com/login.aspx?authtype=ip&custid=s8431878&lang=cs&profile=eds&direct=true&db=nlebk&AN=596616
|
| CAT |
|
|
|c 20220530
|l MUB03
|h 0836
|
| CAT |
|
|
|a VASICEK
|b 02
|c 20220912
|l MUB03
|h 0855
|
| 995 |
|
|
|a eBook
|
| 994 |
- |
1 |
|l MUB03
|l MUB03
|m EBOOK
|1 KUK
|a Knihovna univ. kampusu
|2 EBKUK
|b e-knihy (trvalý nákup)
|5 3307L00005
|8 20220601
|f 83
|f Dálkově přístupná
|r 20220601
|s kup
|
| AVA |
|
|
|a MED50
|b KUK
|c e-knihy (trvalý nákup)
|e available
|t K dispozici
|f 1
|g 0
|h N
|i 0
|j EBKUK
|
